Inhalation CDMO Market to Reach $16.68B by 2035 at 5.7% CAGR

Rising respiratory disease prevalence and advancements in inhalation technologies drive steady market growth.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

The global inhalation CDMO market is projected to expand from $9.13 billion in 2025 to $16.68 billion by 2035, reflecting a steady compound annual growth rate (CAGR) of 5.7% over the forecast period. This growth is propelled by the rising prevalence of respiratory diseases, continuous advancements in inhalation drug delivery technologies, and increasing reliance on outsourced specialized manufacturing services.

Why it matters

The inhalation CDMO market benefits from multiple structural tailwinds, including the increasing global prevalence of respiratory disorders, advancements in inhalation technologies that enhance drug delivery efficiency, and the integration of digital features in inhalation devices that enable real-time monitoring and better treatment management.

The details

The commercial segment leads the inhalation CDMO market with a 70.2% share in 2025, driven by surging requirements for large-scale, cost-effective production of inhalation products. Key growth drivers include the trend toward personalized medicine and targeted inhalation therapies, rising life expectancy contributing to higher COPD prevalence, and the digitalization of healthcare through connected inhaler devices.

  • The inhalation CDMO market is projected to grow from $9.13 billion in 2025 to $16.68 billion by 2035.

The players

Recipharm AB

A leading contract development and manufacturing organization (CDMO) that provides services for the pharmaceutical and biotechnology industries.

Catalent

A global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products.

Lonza Group

A Swiss-based life sciences company that provides products and services to the pharmaceutical, biotech, and specialty ingredients markets.

Got photos? Submit your photos here. ›

The takeaway

The inhalation CDMO market is poised for steady growth, driven by the rising prevalence of respiratory diseases, advancements in inhalation technologies, and the increasing reliance on outsourced specialized manufacturing services within the pharmaceutical sector.